271 related articles for article (PubMed ID: 37559726)
1. Divergent adaptive immune responses define two types of long COVID.
Kervevan J; Staropoli I; Slama D; Jeger-Madiot R; Donnadieu F; Planas D; Pietri MP; Loghmari-Bouchneb W; Alaba Tanah M; Robinot R; Boufassa F; White M; Salmon-Ceron D; Chakrabarti LA
Front Immunol; 2023; 14():1221961. PubMed ID: 37559726
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
[TBL] [Abstract][Full Text] [Related]
3. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
4. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
[TBL] [Abstract][Full Text] [Related]
5. Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study.
Hvidt AK; Guo H; Andersen R; Lende SSF; Vibholm LK; Søgaard OS; Schleimann MH; Russell V; Cheung AM; Paramithiotis E; Olesen R; Tolstrup M
BMC Immunol; 2023 Nov; 24(1):45. PubMed ID: 37974069
[TBL] [Abstract][Full Text] [Related]
6. Antibody tests for identification of current and past infection with SARS-CoV-2.
Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
[TBL] [Abstract][Full Text] [Related]
8. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
[TBL] [Abstract][Full Text] [Related]
9. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.
Salgado Del Riego E; Saiz ML; Corte-Iglesias V; Leoz Gordillo B; Martin-Martin C; Rodríguez-Pérez M; Escudero D; Lopez-Larrea C; Suarez-Alvarez B
Front Immunol; 2022; 13():942192. PubMed ID: 36275696
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
12. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition.
Limoges MA; Quenum AJI; Chowdhury MMH; Rexhepi F; Namvarpour M; Akbari SA; Rioux-Perreault C; Nandi M; Lucier JF; Lemaire-Paquette S; Premkumar L; Durocher Y; Cantin A; Lévesque S; Dionne IJ; Menendez A; Ilangumaran S; Allard-Chamard H; Piché A; Ramanathan S
Front Immunol; 2023; 14():1223936. PubMed ID: 37809081
[TBL] [Abstract][Full Text] [Related]
14. Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines.
Li D; Calderone R; Nsouli TM; Reznikov E; Bellanti JA
Allergy Asthma Proc; 2022 Sep; 43(5):419-430. PubMed ID: 36065108
[No Abstract] [Full Text] [Related]
15. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
16. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses.
Zens KD; Llanas-Cornejo D; Menges D; Fehr JS; Münz C; Puhan MA; Frei A
Int J Infect Dis; 2023 Aug; 133():18-26. PubMed ID: 37149211
[TBL] [Abstract][Full Text] [Related]
18. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2.
Yin K; Peluso MJ; Luo X; Thomas R; Shin MG; Neidleman J; Andrew A; Young KC; Ma T; Hoh R; Anglin K; Huang B; Argueta U; Lopez M; Valdivieso D; Asare K; Deveau TM; Munter SE; Ibrahim R; Ständker L; Lu S; Goldberg SA; Lee SA; Lynch KL; Kelly JD; Martin JN; Münch J; Deeks SG; Henrich TJ; Roan NR
Nat Immunol; 2024 Feb; 25(2):218-225. PubMed ID: 38212464
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
[TBL] [Abstract][Full Text] [Related]
20. Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes.
Rzymski P; Niedziela J; Poniedziałek B; Rosińska J; Zarębska-Michaluk D; Sobala-Szczygieł B; Flisiak R; Gąsior M; Jaroszewicz J
Virology; 2024 Aug; 596():110118. PubMed ID: 38805803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]